Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of December 2018. The report primarily addresses the final resolution of a legal matter initiated in June 2015 regarding a class action lawsuit filed in the District Court of Tel-Aviv.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to legal expenses: the Company was previously awarded NIS 50,000 (approximately $13,500) in expenses by the District Court in July 2017, which was subsequently ordered to be returned to the claimant.
Material Changes
The material change reported is the final dismissal of the pending class action lawsuit. On December 5, 2018, the Supreme Court of Israel dismissed the claimant's appeal of the District Court's decision. As part of a compromise to end the appeal, the Supreme Court ordered the Company to return the previously awarded NIS 50,000 in legal expenses to the claimant.
Outlook, Risks, and Contingencies
The filing indicates that the lawsuit is no longer pending against the Company. There is no management commentary, forward-looking guidance, or discussion of new risks or contingencies in this specific report.
Investor Verification Points
- Confirm the final status of the class action lawsuit is "dismissed" with no further legal exposure.
- Verify the cash outflow of approximately $13,500 required to return the legal expense award to the claimant.
- Note that this filing contains no operational or financial performance data for the period.